Biotinylated Synthetic Chemokines: Their Use for the Development of Nonradioactive Whole-Cell Binding Assays

Abstract

A chemokine binding assay on whole cells was developed using biotinylated synthetic CCL22 as a model ligand. CCL22 analogues were produced by a chemical route, resulting in > 97% homogeneous and defined polypeptides. First, the 5 biotinylated CCL22 analogues synthesized were captured by agarose-immobilized streptavidin, indicating that the biotin molecules introduced in positions G1, K27, K49, K61, and K66 of CCL22 were accessible for binding. Then, it was established using a migration assay that the biotinylated chemokines were at least as biologically active as the unmodified CCL22 form. Subsequently, the biotinylated chemokines were evaluated in an FACS-based whole-cell binding assay. Surprisingly, only the CCL22 analogue with the biotin in position K66 constituted a suitable staining reagent for CCR4-positive cells. Finally, binding characteristics and reproducibility of the binding assay were outlined for the CCL22 analogue with the biotin in position K66. These results exemplified that biotinylated synthetic chemokines constitute promising ligands for the development of chemokine receptor-binding assays on whole cells, provided the position of the biotin moiety introduced along the sequence is adequately chosen. (Journal of Biomolecular Screening 2003:316-323)

References

1. Rossi D, Zlotnik A: The biology of chemokines and their receptors . Annu Rev Immunol 2000;18: 217-242 .

2. Sallusto F, Mackay CR, Lanzavecchia A: The role of chemokine receptors in primary, effector, and memory immune responses . Annu Rev Immunol 2000;18: 593-620 .

3. Horuk R: Chemokine receptors . Cyt Growth Fact Rev 2001;12: 313-335 .

4. Fernandez EJ, Lolis E: Structure, function, and inhibition of chemokines . Annu Rev Pharmacol Toxicol 2002;42: 469-499 .

5. Proudfoot AEI: Chemokine receptors: multifaceted therapeutic targets . Nature Reviews Immunol 2002;2: 106-115 .

6. Hayes IM, Jordan NJ, Towers S, Smith G, Paterson JR, Earnshaw JJ, et al: Human vascular smooth muscle cells express receptors for CC chemokines . Arterioscler Thromb Vasc Biol 1998;18: 397-403 .

7. Andjelkovic AV, Spencer DD, Pachter JS: Visualization of chemokine binding sites on human brain microvessels . J Cell Biol 1999;145: 403-412 .

8. Zhu L, Bisgaier CL, Aviram M, Newton RS: 9-cis retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells . Arterioscler Thromb Vasc Biol 1999;19: 2105-2111 .

9. Yoshimura T, Leonard EJ: Identification of high affinity receptors for human monocyte chemoattractant protein-1 on human monocytes . J Immunol 1990;145: 292-297 .

10.

10. Sato H, Hayashi E, Yamada N, Yatagai M, Takahara Y: Further studies on the site-specific protein modification by microbial transglutaminase . Bioconjug Chem 2001;12: 701-710 .

11.

11. Luster AD: Antichemokine immunotherapy for allergic diseases . Curr Opin Allergy Clin Immunol 2001;1: 561-567 .

12.

12. Romagnani S: Cytokines and chemoattractants in allergic inflammation . Mol Immunol 2002;38: 881-885 .

13.

13. Roggero MA, Meraldi V, Lopez JA, Eberl G, Romero JC, Matile H, et al: The synthetic, oxidized C-terminal fragment of the Plasmodium berghei circumsporozoite protein elicits a high protective response . Eur J Immunol 2000;30: 2679-2685 .

14.

14. Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G, et al: The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3 . J Biol Chem 2001;276: 2986-2991 .

15.

15. Hemmerich S, Paavola C, Bloom A, Bhakta S, Freedman R, Grunberger D, et al: Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2 . Biochemistry 1999;38: 13013-13025 .

16.

16. Jarnagin K, Grunberger D, Mulkins M, Wong B, Hemmerich S, Paavola C, et al: Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2 . Biochemistry 1999;38: 16167-16177 .

17.

17. Struyf S, Proost P, Sozzani S, Mantovani A, Wuyts A, De Clercq E, et al: Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor . J Immunol 1998;161: 2672-2675 .

18.

18. Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J: Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist . Blood 2000;96: 1674-1680 .